Selected research
Market Outlook & Growth Opportunities
Global Premarital Genetic Testing Market Outlook and Growth Opportunities 2026
Market perspective
The global Premarital Genetic Testing market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.
The North America market for Premarital Genetic Testing is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
The Europe market for Premarital Genetic Testing is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
Read the full market overview
The Asia Pacific market for Premarital Genetic Testing is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
In China, the Premarital Genetic Testing market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
Major global companies in the Premarital Genetic Testing market include NxGen MDx, LLC, OPKO Health, Gene by Gene, Sonic Genetics, MedGenome Labs, Centogene, LSI Medience, GC Genome and Illumina, among others. In 2025, the top three vendors together accounted for approximately % of global market revenue.
This report provides an overview of the global Premarital Genetic Testing market in terms of revenue and gross margin, analyzing global market trends using historical revenue data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.
The study covers key producers of Premarital Genetic Testing and market revenue by major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.
The report also presents Premarital Genetic Testing revenue, market share, and industry ranking for the main companies for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.
Across the 2021-2026 period, the analysis compares revenue growth and profitability profiles by company, distinguishing participants with sustained expansion from those with more cyclical performance, and relates these patterns to differences in regional exposure, product portfolios, and application focus in the global Premarital Genetic Testing market.
Premarital Genetic Testing Segment by Company
NxGen MDx, LLC
OPKO Health
Gene by Gene
Sonic Genetics
MedGenome Labs
Centogene
LSI Medience
GC Genome
Illumina
Fulgent Genetics
Natera
Clinical Labs
Eurofins Scientific
Myriad Genetics
Thermo Fisher Scientific
Genoma Group
SRL Inc.
Seegene
Huizhi Gene
My Baby Company
Invitae
Dian Diagnostics Group
Adicon
BGI
WuXi AppTec
Novogene
Berry Genomics
Kingmed Diagnostic
Zhongyuan Concord
AmoyDx
Premarital Genetic Testing Segment by Type
Single-Gene Genetic Disease Testing
Chromosomal Structural And Numerical Abnormality Testing
Polygenic Disease Risk Assessment
Mitochondrial And Maternal Genetic Testing
Pharmacogenomics And Functional Gene Testing
Premarital Genetic Testing Segment by Application
Male
Female
Premarital Genetic Testing Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Colombia
Middle East & Africa
Egypt
South Africa
Israel
Türkiye
GCC Countries
Study Objectives
1. To analyze and research the global Premarital Genetic Testing status and future forecast, involving, revenue, growth rate (CAGR), market share, historical and forecast.
2. To present the Premarital Genetic Testing key companies, revenue, market share, and recent developments.
3. To split the Premarital Genetic Testing breakdown data by regions, type, companies, and application.
4. To analyze the global and key regions Premarital Genetic Testing market potential and advantage, opportunity and challenge, restraints, and risks.
5. To identify Premarital Genetic Testing significant trends, drivers, influence factors in global and regions.
6. To analyze Premarital Genetic Testing competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Premarital Genetic Testing market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Premarital Genetic Testing and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Premarital Genetic Testing.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Introduces the report scope of the report, global total market size.
Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Premarital Genetic Testing industry.
Chapter 3: Detailed analysis of Premarital Genetic Testing company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales value of Premarital Genetic Testing in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of key country in the world.
Chapter 7: Sales value of Premarital Genetic Testing in country level. It provides sigmate data by type, and by application for each country/region.
Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.
Chapter 9: Concluding Insights.
More report detail
Tables and figures
Scope & coverage.
Types
- Single-Gene Genetic Disease Testing
- Chromosomal Structural And Numerical Abnormality Testing
- Polygenic Disease Risk Assessment
- Mitochondrial And Maternal Genetic Testing
- Pharmacogenomics And Functional Gene Testing
Applications
- Male
- Female
Companies covered
- NxGen MDx, LLC
- OPKO Health
- Gene by Gene
- Sonic Genetics
- MedGenome Labs
- Centogene
- LSI Medience
- GC Genome
- Illumina
- Fulgent Genetics
- Natera
- Clinical Labs
- Eurofins Scientific
- Myriad Genetics
- Thermo Fisher Scientific
- Genoma Group
- SRL Inc.
- Seegene
- Huizhi Gene
- My Baby Company
- Invitae
- Dian Diagnostics Group
- Adicon
- BGI
- WuXi AppTec
- Novogene
- Berry Genomics
- Kingmed Diagnostic
- Zhongyuan Concord
- AmoyDx
Inside the report.
1 Market Overview
- 1.1 Product Definition
- 1.2 Global Premarital Genetic Testing Market Size, 2021 VS 2025 VS 2032
- 1.3 Global Premarital Genetic Testing Market Size (2021-2032)
- 1.4 Assumptions and Limitations
- 1.5 Study Goals and Objectives
2 Premarital Genetic Testing Market Dynamics
- 2.1 Premarital Genetic Testing Industry Trends
- 2.2 Premarital Genetic Testing Industry Drivers
- 2.3 Premarital Genetic Testing Industry Opportunities and Challenges
- 2.4 Premarital Genetic Testing Industry Restraints
3 Premarital Genetic Testing Market by Company
- 3.1 Global Premarital Genetic Testing Company Revenue Ranking in 2025
- 3.2 Global Premarital Genetic Testing Revenue by Company (2021-2026)
- 3.3 Global Premarital Genetic Testing Company Ranking (2024-2026)
- 3.4 Global Premarital Genetic Testing Company Manufacturing Base and Headquarters
- 3.5 Global Premarital Genetic Testing Company Product Type and Application
- 3.6 Global Premarital Genetic Testing Company Establishment Date
- 3.7 Market Competitive Analysis
- 3.7.1 Global Premarital Genetic Testing Market Concentration Ratio (CR5 and HHI)
- 3.7.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
- 3.7.3 2025 Premarital Genetic Testing Tier 1, Tier 2, and Tier 3 Companies
- 3.8 Mergers and Acquisitions Expansion
4 Premarital Genetic Testing Market by Type
- 4.1 Premarital Genetic Testing Type Introduction
- 4.1.1 Single-Gene Genetic Disease Testing
- 4.1.2 Chromosomal Structural And Numerical Abnormality Testing
- 4.1.3 Polygenic Disease Risk Assessment
- 4.1.4 Mitochondrial And Maternal Genetic Testing
- 4.1.5 Pharmacogenomics And Functional Gene Testing
- 4.2 Global Premarital Genetic Testing Sales Value by Type
- 4.2.1 Global Premarital Genetic Testing Sales Value by Type (2021 VS 2025 VS 2032)
- 4.2.2 Global Premarital Genetic Testing Sales Value by Type (2021-2032)
- 4.2.3 Global Premarital Genetic Testing Sales Value Share by Type (2021-2032)
5 Premarital Genetic Testing Market by Application
- 5.1 Premarital Genetic Testing Application Introduction
- 5.1.1 Male
- 5.1.2 Female
- 5.2 Global Premarital Genetic Testing Sales Value by Application
- 5.2.1 Global Premarital Genetic Testing Sales Value by Application (2021 VS 2025 VS 2032)
- 5.2.2 Global Premarital Genetic Testing Sales Value by Application (2021-2032)
- 5.2.3 Global Premarital Genetic Testing Sales Value Share by Application (2021-2032)
6 Premarital Genetic Testing Regional Value Analysis
- 6.1 Global Premarital Genetic Testing Sales Value by Region: 2021 VS 2025 VS 2032
- 6.2 Global Premarital Genetic Testing Sales Value by Region (2021-2032)
- 6.2.1 Global Premarital Genetic Testing Sales Value by Region: 2021-2026
- 6.2.2 Global Premarital Genetic Testing Sales Value by Region (2027-2032)
- 6.3 North America
- 6.3.1 North America Premarital Genetic Testing Sales Value (2021-2032)
- 6.3.2 North America Premarital Genetic Testing Sales Value Share by Country, 2025 VS 2032
- 6.4 Europe
- 6.4.1 Europe Premarital Genetic Testing Sales Value (2021-2032)
- 6.4.2 Europe Premarital Genetic Testing Sales Value Share by Country, 2025 VS 2032
- 6.5 Asia-Pacific
- 6.5.1 Asia-Pacific Premarital Genetic Testing Sales Value (2021-2032)
- 6.5.2 Asia-Pacific Premarital Genetic Testing Sales Value Share by Country, 2025 VS 2032
- 6.6 South America
- 6.6.1 South America Premarital Genetic Testing Sales Value (2021-2032)
- 6.6.2 South America Premarital Genetic Testing Sales Value Share by Country, 2025 VS 2032
- 6.7 Middle East & Africa
- 6.7.1 Middle East & Africa Premarital Genetic Testing Sales Value (2021-2032)
- 6.7.2 Middle East & Africa Premarital Genetic Testing Sales Value Share by Country, 2025 VS 2032
7 Premarital Genetic Testing Country-level Value Analysis
- 7.1 Global Premarital Genetic Testing Sales Value by Country: 2021 VS 2025 VS 2032
- 7.2 Global Premarital Genetic Testing Sales Value by Country (2021-2032)
- 7.2.1 Global Premarital Genetic Testing Sales Value by Country (2021-2026)
- 7.2.2 Global Premarital Genetic Testing Sales Value by Country (2027-2032)
- 7.3 USA
- 7.3.1 USA Premarital Genetic Testing Sales Value Growth Rate (2021-2032)
- 7.3.2 USA Premarital Genetic Testing Sales Value Share by Type, 2025 VS 2032
- 7.3.3 USA Premarital Genetic Testing Sales Value Share by Application, 2025 VS 2032
- 7.4 Canada
- 7.4.1 Canada Premarital Genetic Testing Sales Value Growth Rate (2021-2032)
- 7.4.2 Canada Premarital Genetic Testing Sales Value Share by Type, 2025 VS 2032
- 7.4.3 Canada Premarital Genetic Testing Sales Value Share by Application, 2025 VS 2032
- 7.5 Mexico
- 7.5.1 Mexico Premarital Genetic Testing Sales Value Growth Rate (2021-2032)
- 7.5.2 Mexico Premarital Genetic Testing Sales Value Share by Type, 2025 VS 2032
- 7.5.3 Mexico Premarital Genetic Testing Sales Value Share by Application, 2025 VS 2032
- 7.6 Germany
- 7.6.1 Germany Premarital Genetic Testing Sales Value Growth Rate (2021-2032)
- 7.6.2 Germany Premarital Genetic Testing Sales Value Share by Type, 2025 VS 2032
- 7.6.3 Germany Premarital Genetic Testing Sales Value Share by Application, 2025 VS 2032
- 7.7 France
- 7.7.1 France Premarital Genetic Testing Sales Value Growth Rate (2021-2032)
- 7.7.2 France Premarital Genetic Testing Sales Value Share by Type, 2025 VS 2032
- 7.7.3 France Premarital Genetic Testing Sales Value Share by Application, 2025 VS 2032
- 7.8 U.K.
- 7.8.1 U.K. Premarital Genetic Testing Sales Value Growth Rate (2021-2032)
- 7.8.2 U.K. Premarital Genetic Testing Sales Value Share by Type, 2025 VS 2032
- 7.8.3 U.K. Premarital Genetic Testing Sales Value Share by Application, 2025 VS 2032
- 7.9 Italy
- 7.9.1 Italy Premarital Genetic Testing Sales Value Growth Rate (2021-2032)
- 7.9.2 Italy Premarital Genetic Testing Sales Value Share by Type, 2025 VS 2032
- 7.9.3 Italy Premarital Genetic Testing Sales Value Share by Application, 2025 VS 2032
- 7.10 Spain
- 7.10.1 Spain Premarital Genetic Testing Sales Value Growth Rate (2021-2032)
- 7.10.2 Spain Premarital Genetic Testing Sales Value Share by Type, 2025 VS 2032
- 7.10.3 Spain Premarital Genetic Testing Sales Value Share by Application, 2025 VS 2032
- 7.11 Russia
- 7.11.1 Russia Premarital Genetic Testing Sales Value Growth Rate (2021-2032)
- 7.11.2 Russia Premarital Genetic Testing Sales Value Share by Type, 2025 VS 2032
- 7.11.3 Russia Premarital Genetic Testing Sales Value Share by Application, 2025 VS 2032
- 7.12 Netherlands
- 7.12.1 Netherlands Premarital Genetic Testing Sales Value Growth Rate (2021-2032)
- 7.12.2 Netherlands Premarital Genetic Testing Sales Value Share by Type, 2025 VS 2032
- 7.12.3 Netherlands Premarital Genetic Testing Sales Value Share by Application, 2025 VS 2032
- 7.13 Nordic Countries
- 7.13.1 Nordic Countries Premarital Genetic Testing Sales Value Growth Rate (2021-2032)
- 7.13.2 Nordic Countries Premarital Genetic Testing Sales Value Share by Type, 2025 VS 2032
- 7.13.3 Nordic Countries Premarital Genetic Testing Sales Value Share by Application, 2025 VS 2032
- 7.14 China
- 7.14.1 China Premarital Genetic Testing Sales Value Growth Rate (2021-2032)
- 7.14.2 China Premarital Genetic Testing Sales Value Share by Type, 2025 VS 2032
- 7.14.3 China Premarital Genetic Testing Sales Value Share by Application, 2025 VS 2032
- 7.15 Japan
- 7.15.1 Japan Premarital Genetic Testing Sales Value Growth Rate (2021-2032)
- 7.15.2 Japan Premarital Genetic Testing Sales Value Share by Type, 2025 VS 2032
- 7.15.3 Japan Premarital Genetic Testing Sales Value Share by Application, 2025 VS 2032
- 7.16 South Korea
- 7.16.1 South Korea Premarital Genetic Testing Sales Value Growth Rate (2021-2032)
- 7.16.2 South Korea Premarital Genetic Testing Sales Value Share by Type, 2025 VS 2032
- 7.16.3 South Korea Premarital Genetic Testing Sales Value Share by Application, 2025 VS 2032
- 7.17 India
- 7.17.1 India Premarital Genetic Testing Sales Value Growth Rate (2021-2032)
- 7.17.2 India Premarital Genetic Testing Sales Value Share by Type, 2025 VS 2032
- 7.17.3 India Premarital Genetic Testing Sales Value Share by Application, 2025 VS 2032
- 7.18 Australia
- 7.18.1 Australia Premarital Genetic Testing Sales Value Growth Rate (2021-2032)
- 7.18.2 Australia Premarital Genetic Testing Sales Value Share by Type, 2025 VS 2032
- 7.18.3 Australia Premarital Genetic Testing Sales Value Share by Application, 2025 VS 2032
- 7.19 Southeast Asia
- 7.19.1 Southeast Asia Premarital Genetic Testing Sales Value Growth Rate (2021-2032)
- 7.19.2 Southeast Asia Premarital Genetic Testing Sales Value Share by Type, 2025 VS 2032
- 7.19.3 Southeast Asia Premarital Genetic Testing Sales Value Share by Application, 2025 VS 2032
- 7.20 Brazil
- 7.20.1 Brazil Premarital Genetic Testing Sales Value Growth Rate (2021-2032)
- 7.20.2 Brazil Premarital Genetic Testing Sales Value Share by Type, 2025 VS 2032
- 7.20.3 Brazil Premarital Genetic Testing Sales Value Share by Application, 2025 VS 2032
- 7.21 Argentina
- 7.21.1 Argentina Premarital Genetic Testing Sales Value Growth Rate (2021-2032)
- 7.21.2 Argentina Premarital Genetic Testing Sales Value Share by Type, 2025 VS 2032
- 7.21.3 Argentina Premarital Genetic Testing Sales Value Share by Application, 2025 VS 2032
- 7.22 Chile
- 7.22.1 Chile Premarital Genetic Testing Sales Value Growth Rate (2021-2032)
- 7.22.2 Chile Premarital Genetic Testing Sales Value Share by Type, 2025 VS 2032
- 7.22.3 Chile Premarital Genetic Testing Sales Value Share by Application, 2025 VS 2032
- 7.23 Colombia
- 7.23.1 Colombia Premarital Genetic Testing Sales Value Growth Rate (2021-2032)
- 7.23.2 Colombia Premarital Genetic Testing Sales Value Share by Type, 2025 VS 2032
- 7.23.3 Colombia Premarital Genetic Testing Sales Value Share by Application, 2025 VS 2032
- 7.24 Peru
- 7.24.1 Peru Premarital Genetic Testing Sales Value Growth Rate (2021-2032)
- 7.24.2 Peru Premarital Genetic Testing Sales Value Share by Type, 2025 VS 2032
- 7.24.3 Peru Premarital Genetic Testing Sales Value Share by Application, 2025 VS 2032
- 7.25 Saudi Arabia
- 7.25.1 Saudi Arabia Premarital Genetic Testing Sales Value Growth Rate (2021-2032)
- 7.25.2 Saudi Arabia Premarital Genetic Testing Sales Value Share by Type, 2025 VS 2032
- 7.25.3 Saudi Arabia Premarital Genetic Testing Sales Value Share by Application, 2025 VS 2032
- 7.26 Israel
- 7.26.1 Israel Premarital Genetic Testing Sales Value Growth Rate (2021-2032)
- 7.26.2 Israel Premarital Genetic Testing Sales Value Share by Type, 2025 VS 2032
- 7.26.3 Israel Premarital Genetic Testing Sales Value Share by Application, 2025 VS 2032
- 7.27 UAE
- 7.27.1 UAE Premarital Genetic Testing Sales Value Growth Rate (2021-2032)
- 7.27.2 UAE Premarital Genetic Testing Sales Value Share by Type, 2025 VS 2032
- 7.27.3 UAE Premarital Genetic Testing Sales Value Share by Application, 2025 VS 2032
- 7.28 Turkey
- 7.28.1 Turkey Premarital Genetic Testing Sales Value Growth Rate (2021-2032)
- 7.28.2 Turkey Premarital Genetic Testing Sales Value Share by Type, 2025 VS 2032
- 7.28.3 Turkey Premarital Genetic Testing Sales Value Share by Application, 2025 VS 2032
- 7.29 Iran
- 7.29.1 Iran Premarital Genetic Testing Sales Value Growth Rate (2021-2032)
- 7.29.2 Iran Premarital Genetic Testing Sales Value Share by Type, 2025 VS 2032
- 7.29.3 Iran Premarital Genetic Testing Sales Value Share by Application, 2025 VS 2032
- 7.30 Egypt
- 7.30.1 Egypt Premarital Genetic Testing Sales Value Growth Rate (2021-2032)
- 7.30.2 Egypt Premarital Genetic Testing Sales Value Share by Type, 2025 VS 2032
- 7.30.3 Egypt Premarital Genetic Testing Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
- 8.1 NxGen MDx, LLC
- 8.1.1 NxGen MDx, LLC Company Information
- 8.1.2 NxGen MDx, LLC Business Overview
- 8.1.3 NxGen MDx, LLC Premarital Genetic Testing Revenue and Gross Margin (2021-2026)
- 8.1.4 NxGen MDx, LLC Premarital Genetic Testing Product Portfolio
- 8.1.5 NxGen MDx, LLC Recent Developments
- 8.2 OPKO Health
- 8.2.1 OPKO Health Company Information
- 8.2.2 OPKO Health Business Overview
- 8.2.3 OPKO Health Premarital Genetic Testing Revenue and Gross Margin (2021-2026)
- 8.2.4 OPKO Health Premarital Genetic Testing Product Portfolio
- 8.2.5 OPKO Health Recent Developments
- 8.3 Gene by Gene
- 8.3.1 Gene by Gene Company Information
- 8.3.2 Gene by Gene Business Overview
- 8.3.3 Gene by Gene Premarital Genetic Testing Revenue and Gross Margin (2021-2026)
- 8.3.4 Gene by Gene Premarital Genetic Testing Product Portfolio
- 8.3.5 Gene by Gene Recent Developments
- 8.4 Sonic Genetics
- 8.4.1 Sonic Genetics Company Information
- 8.4.2 Sonic Genetics Business Overview
- 8.4.3 Sonic Genetics Premarital Genetic Testing Revenue and Gross Margin (2021-2026)
- 8.4.4 Sonic Genetics Premarital Genetic Testing Product Portfolio
- 8.4.5 Sonic Genetics Recent Developments
- 8.5 MedGenome Labs
- 8.5.1 MedGenome Labs Company Information
- 8.5.2 MedGenome Labs Business Overview
- 8.5.3 MedGenome Labs Premarital Genetic Testing Revenue and Gross Margin (2021-2026)
- 8.5.4 MedGenome Labs Premarital Genetic Testing Product Portfolio
- 8.5.5 MedGenome Labs Recent Developments
- 8.6 Centogene
- 8.6.1 Centogene Company Information
- 8.6.2 Centogene Business Overview
- 8.6.3 Centogene Premarital Genetic Testing Revenue and Gross Margin (2021-2026)
- 8.6.4 Centogene Premarital Genetic Testing Product Portfolio
- 8.6.5 Centogene Recent Developments
- 8.7 LSI Medience
- 8.7.1 LSI Medience Company Information
- 8.7.2 LSI Medience Business Overview
- 8.7.3 LSI Medience Premarital Genetic Testing Revenue and Gross Margin (2021-2026)
- 8.7.4 LSI Medience Premarital Genetic Testing Product Portfolio
- 8.7.5 LSI Medience Recent Developments
- 8.8 GC Genome
- 8.8.1 GC Genome Company Information
- 8.8.2 GC Genome Business Overview
- 8.8.3 GC Genome Premarital Genetic Testing Revenue and Gross Margin (2021-2026)
- 8.8.4 GC Genome Premarital Genetic Testing Product Portfolio
- 8.8.5 GC Genome Recent Developments
- 8.9 Illumina
- 8.9.1 Illumina Company Information
- 8.9.2 Illumina Business Overview
- 8.9.3 Illumina Premarital Genetic Testing Revenue and Gross Margin (2021-2026)
- 8.9.4 Illumina Premarital Genetic Testing Product Portfolio
- 8.9.5 Illumina Recent Developments
- 8.10 Fulgent Genetics
- 8.10.1 Fulgent Genetics Company Information
- 8.10.2 Fulgent Genetics Business Overview
- 8.10.3 Fulgent Genetics Premarital Genetic Testing Revenue and Gross Margin (2021-2026)
- 8.10.4 Fulgent Genetics Premarital Genetic Testing Product Portfolio
- 8.10.5 Fulgent Genetics Recent Developments
- 8.11 Natera
- 8.11.1 Natera Company Information
- 8.11.2 Natera Business Overview
- 8.11.3 Natera Premarital Genetic Testing Revenue and Gross Margin (2021-2026)
- 8.11.4 Natera Premarital Genetic Testing Product Portfolio
- 8.11.5 Natera Recent Developments
- 8.12 Clinical Labs
- 8.12.1 Clinical Labs Company Information
- 8.12.2 Clinical Labs Business Overview
- 8.12.3 Clinical Labs Premarital Genetic Testing Revenue and Gross Margin (2021-2026)
- 8.12.4 Clinical Labs Premarital Genetic Testing Product Portfolio
- 8.12.5 Clinical Labs Recent Developments
- 8.13 Eurofins Scientific
- 8.13.1 Eurofins Scientific Company Information
- 8.13.2 Eurofins Scientific Business Overview
- 8.13.3 Eurofins Scientific Premarital Genetic Testing Revenue and Gross Margin (2021-2026)
- 8.13.4 Eurofins Scientific Premarital Genetic Testing Product Portfolio
- 8.13.5 Eurofins Scientific Recent Developments
- 8.14 Myriad Genetics
- 8.14.1 Myriad Genetics Company Information
- 8.14.2 Myriad Genetics Business Overview
- 8.14.3 Myriad Genetics Premarital Genetic Testing Revenue and Gross Margin (2021-2026)
- 8.14.4 Myriad Genetics Premarital Genetic Testing Product Portfolio
- 8.14.5 Myriad Genetics Recent Developments
- 8.15 Thermo Fisher Scientific
- 8.15.1 Thermo Fisher Scientific Company Information
- 8.15.2 Thermo Fisher Scientific Business Overview
- 8.15.3 Thermo Fisher Scientific Premarital Genetic Testing Revenue and Gross Margin (2021-2026)
- 8.15.4 Thermo Fisher Scientific Premarital Genetic Testing Product Portfolio
- 8.15.5 Thermo Fisher Scientific Recent Developments
- 8.16 Genoma Group
- 8.16.1 Genoma Group Company Information
- 8.16.2 Genoma Group Business Overview
- 8.16.3 Genoma Group Premarital Genetic Testing Revenue and Gross Margin (2021-2026)
- 8.16.4 Genoma Group Premarital Genetic Testing Product Portfolio
- 8.16.5 Genoma Group Recent Developments
- 8.17 SRL Inc.
- 8.17.1 SRL Inc. Company Information
- 8.17.2 SRL Inc. Business Overview
- 8.17.3 SRL Inc. Premarital Genetic Testing Revenue and Gross Margin (2021-2026)
- 8.17.4 SRL Inc. Premarital Genetic Testing Product Portfolio
- 8.17.5 SRL Inc. Recent Developments
- 8.18 Seegene
- 8.18.1 Seegene Company Information
- 8.18.2 Seegene Business Overview
- 8.18.3 Seegene Premarital Genetic Testing Revenue and Gross Margin (2021-2026)
- 8.18.4 Seegene Premarital Genetic Testing Product Portfolio
- 8.18.5 Seegene Recent Developments
- 8.19 Huizhi Gene
- 8.19.1 Huizhi Gene Company Information
- 8.19.2 Huizhi Gene Business Overview
- 8.19.3 Huizhi Gene Premarital Genetic Testing Revenue and Gross Margin (2021-2026)
- 8.19.4 Huizhi Gene Premarital Genetic Testing Product Portfolio
- 8.19.5 Huizhi Gene Recent Developments
- 8.20 My Baby Company
- 8.20.1 My Baby Company Company Information
- 8.20.2 My Baby Company Business Overview
- 8.20.3 My Baby Company Premarital Genetic Testing Revenue and Gross Margin (2021-2026)
- 8.20.4 My Baby Company Premarital Genetic Testing Product Portfolio
- 8.20.5 My Baby Company Recent Developments
- 8.21 Invitae
- 8.21.1 Invitae Company Information
- 8.21.2 Invitae Business Overview
- 8.21.3 Invitae Premarital Genetic Testing Revenue and Gross Margin (2021-2026)
- 8.21.4 Invitae Premarital Genetic Testing Product Portfolio
- 8.21.5 Invitae Recent Developments
- 8.22 Dian Diagnostics Group
- 8.22.1 Dian Diagnostics Group Company Information
- 8.22.2 Dian Diagnostics Group Business Overview
- 8.22.3 Dian Diagnostics Group Premarital Genetic Testing Revenue and Gross Margin (2021-2026)
- 8.22.4 Dian Diagnostics Group Premarital Genetic Testing Product Portfolio
- 8.22.5 Dian Diagnostics Group Recent Developments
- 8.23 Adicon
- 8.23.1 Adicon Company Information
- 8.23.2 Adicon Business Overview
- 8.23.3 Adicon Premarital Genetic Testing Revenue and Gross Margin (2021-2026)
- 8.23.4 Adicon Premarital Genetic Testing Product Portfolio
- 8.23.5 Adicon Recent Developments
- 8.24 BGI
- 8.24.1 BGI Company Information
- 8.24.2 BGI Business Overview
- 8.24.3 BGI Premarital Genetic Testing Revenue and Gross Margin (2021-2026)
- 8.24.4 BGI Premarital Genetic Testing Product Portfolio
- 8.24.5 BGI Recent Developments
- 8.25 WuXi AppTec
- 8.25.1 WuXi AppTec Company Information
- 8.25.2 WuXi AppTec Business Overview
- 8.25.3 WuXi AppTec Premarital Genetic Testing Revenue and Gross Margin (2021-2026)
- 8.25.4 WuXi AppTec Premarital Genetic Testing Product Portfolio
- 8.25.5 WuXi AppTec Recent Developments
- 8.26 Novogene
- 8.26.1 Novogene Company Information
- 8.26.2 Novogene Business Overview
- 8.26.3 Novogene Premarital Genetic Testing Revenue and Gross Margin (2021-2026)
- 8.26.4 Novogene Premarital Genetic Testing Product Portfolio
- 8.26.5 Novogene Recent Developments
- 8.27 Berry Genomics
- 8.27.1 Berry Genomics Company Information
- 8.27.2 Berry Genomics Business Overview
- 8.27.3 Berry Genomics Premarital Genetic Testing Revenue and Gross Margin (2021-2026)
- 8.27.4 Berry Genomics Premarital Genetic Testing Product Portfolio
- 8.27.5 Berry Genomics Recent Developments
- 8.28 Kingmed Diagnostic
- 8.28.1 Kingmed Diagnostic Company Information
- 8.28.2 Kingmed Diagnostic Business Overview
- 8.28.3 Kingmed Diagnostic Premarital Genetic Testing Revenue and Gross Margin (2021-2026)
- 8.28.4 Kingmed Diagnostic Premarital Genetic Testing Product Portfolio
- 8.28.5 Kingmed Diagnostic Recent Developments
- 8.29 Zhongyuan Concord
- 8.29.1 Zhongyuan Concord Company Information
- 8.29.2 Zhongyuan Concord Business Overview
- 8.29.3 Zhongyuan Concord Premarital Genetic Testing Revenue and Gross Margin (2021-2026)
- 8.29.4 Zhongyuan Concord Premarital Genetic Testing Product Portfolio
- 8.29.5 Zhongyuan Concord Recent Developments
- 8.30 AmoyDx
- 8.30.1 AmoyDx Company Information
- 8.30.2 AmoyDx Business Overview
- 8.30.3 AmoyDx Premarital Genetic Testing Revenue and Gross Margin (2021-2026)
- 8.30.4 AmoyDx Premarital Genetic Testing Product Portfolio
- 8.30.5 AmoyDx Recent Developments
9 Concluding Insights
10 Appendix
- 10.1 Reasons for Doing This Study
- 10.2 Research Methodology
- 10.3 Research Process
- 10.4 Authors List of This Report
- 10.5 Data Source
- 10.5.1 Secondary Sources
- 10.5.2 Primary Sources
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst